Jason Loveridge

Jason Loveridge founded Parvulus Suisse SA in 2011, where he worked as Chief Executive Officer from 2011 to 2014 and Invex Therapeutics Ltd.
in 2019, where he worked as Non-Executive Chairman from 2019 to 2023.
Dr. Loveridge also currently works at 4SC AG, as Chief Executive Officer from 2016, Corticrine Ltd., as Director, Warambi Ltd., as Managing Director, and Invex Therapeutics Ltd.
(United Kingdom), as Director.
Dr. Loveridge also formerly worked at Spark Therapeutics Ireland Ltd., as Chief Executive Officer from 2011 to 2016, Arthro Kinetics Ltd., as Chief Executive Officer & Executive Director from 2008 to 2009, Resonance Health Ltd., as Independent Non-Executive Director from 2013 to 2017, Korda & Co., as Director & Investment Manager from 1991 to 1995, Biofrontera AG, as Non-Executive Director, Actinogen Medical Ltd., as Non-Executive Director from 2017 to 2018, Anaconda Pharma SASU, as Director, Warambi SARL, as Executive Director & Owner from 2005 to 2020, JDS BioPharma Pty Ltd., as Director from 2006 to 2020, Parvulus Medical SAS, as Director from 2011 to 2014, IT Asset Management SA, as Gérant Sénior from 2005 to 2007, and BioPharma Capital Ltd., as Principal in 2003.
Dr. Loveridge received his doctorate degree in 1988 from the University of Adelaide and undergraduate degree in 1982 from The University of New South Wales.